172@29@17@102!~!172@29@0@53!~!|news|business|stocks|buy-amrutanjan-targetrs-470-firstcall-research-1488799.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to PRO at just Rs.33 per month. Use code SUPERPRO
Last Updated : Sep 29, 2015 02:16 PM IST | Source: Moneycontrol.com

Buy Amrutanjan; target of Rs 470: Firstcall Research

Firstcall Research is bullish on Amrutanjan and has recommended buy rating on the stock with a target price of Rs 470 in its research report dated September 28, 2015.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Firstcall Research's reserach report on Amrutanjan

Amrutanjan Health Care was started in the year 1893. It is one of the household names in South India. While Amrutanjan Pain Balm (Yellow Balm) is the flagship brand of the company with a rich heritage of over 100 years, the company is also planning to introduce a series of next generation products in healthcare category. The company manufactures Amrutanjan pain balm, Anoleum, Gripe Water, Inhaler, Dermal Ointment, Cetomix cough mixture, Castor Oil, Swas Mints 'Salofin' tablets, Amrutanjan cold rub, 'Hero' Super Pain Balm, Dragon Liquid Balm. With a wide range of ayurvedic and allopathic products, Amrutanjan has helped millions of people relieve themselves from the pain and discomfort of headaches, colds, sprains, muscular pains, rheumatic pains and stands a real pain management specialist for its loyal customers. Amrutanjan is taking action to focus on the competency of each product and its application. The current offerings have been segregated to 3 sub brands: Kick out Pain for pain management, Relief for congestion management and Purity for hygiene products. From R&D to branding, retail activation to advertising communication, Amrutanjan is positioning itself as a specialist in the competitive scenario. The company has diversified into various businesses in the health care segment like the Fine Chemical Division and Osmosys Medical Clinic located in Chennai. The products in the pain care segment, other categories include cough and cold care, health and home care.

We recommend ‘BUY’ in this particular scrip with a target price of Rs. 470.00 for Medium to Long term investment.

For all recommendations, click here

Disclaimer:
The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

First Published on Sep 29, 2015 02:16 pm
Sections